Table 2

Time to relapse of Takayasu arteritis according to various definitions

ITT populationTocilizumab subcutaneous 162 mg/week (n=18)Placebo (n=18)
Protocol definition*
 Patients who relapsed, n (%)8 (44.4)11 (61.1)
 Treatment duration, weeks, median19.0012.86
 Time to relapse,† weeks, median (95% CI)NE (12.1 to NE)12.1 (10.7 to 16.0)
 HR (95.41% CI); p value‡0.41 (0.15 to 1.10); p=0.0596
 Estimated relapse-free rate at week 24, % (95% CI)†50.6 (25.4 to 75.8)22.9 (0.4 to 45.4)
Kerr’s definition§
 Patients who relapsed, n (%)8 (44.4)11 (61.1)
 Time to relapse,† weeks, median (95% CI)NE (12.1 to NE)12.1 (10.7 to 16.0)
 HR (95.41% CI); p value‡0.41 (0.15 to 1.10); p=0.0596
 Estimated relapse-free rate at week 24, % (95% CI)†50.6 (25.4 to 75.8)22.9 (0.4 to 45.4)
Clinical definition¶
 Patients who relapsed, n (%)11 (61.1)11 (61.1)
 Time to relapse,† weeks, median (95% CI)16.0 (8.1 to NE)12.0 (8.3 to 16.0)
 HR (95.41% CI); p value‡0.70 (0.29 to 1.70); p=0.4224
 Estimated relapse-free rate at week 24, % (95% CI)30.0 (5.3 to 54.7)24.6 (1.2 to 48.1)